ITT's Synergy Machine Is Ahead of Plan — So Why Is the Stock 11% Off Its High?

A record 21% margin, 58% order growth and a third guidance raise, yet the revenue-synergy promise quietly walked off the script and the balance sheet now carries a $2.4 billion hole

ITT · Earnings Call · 2026-11-05

The clean quarter, and the line that vanished

On paper there is nothing to argue with. ITT grew orders 58% (20% organic), revenue 44% (8% organic) to over $1.4 billion, and delivered a book-to-bill of 1.08. “We expanded operating margin 140 basis points reaching 21% for the very first time.” — Luca Savi, Chief Executive Officer and President · 2026-11-05 Adjusted EPS of $2.26 rose 20%, year-to-date free cash flow of $464 million was up 26%, and guidance went up again — organic revenue to 7%–9%, margin to roughly 20.6%, EPS to $8.58 at the midpoint, free cash flow to $610 million. The low end of the new EPS range now sits above the high end of the old one. The organic orders line and the higher backlog narrative are the load-bearing beams of the whole story. And yet the stock sits roughly 11% below its April peak of $221.69, having gone sideways for six months while estimates climbed. That divergence is the interesting part. One explanation lives in what management stopped saying. In the second quarter, revenue synergy was a top-ten keyword in this company's own keyword set. This quarter it is gone from the top thirty entirely — replaced by the blander "performance of SPX FLOW." Luca Savi was unusually candid about why: “revenue synergies, it takes time... This is really why we didn't put them in the model.” — Luca Savi, Chief Executive Officer and President · 2026-11-05 That is consistent with May's framing that cross-selling would land “most likely starting 2027” — Emmanuel Caprais, Chief Financial Officer · 2026-02-05 — but consistent-with-previous-guidance is not the same as delivering. Cost synergies are running well ahead (over $20 million by year-end against a $15 million target, a greater-than-$30-million run rate against an original $80 million program); the growth half of the value-creation equation is still a slide, not a number.

CCT inherits the crown

The genuinely new strategic fact this quarter is a leadership re-wiring. Davide Barbon, who runs Motion Technologies, now also takes Connect & Control Technologies. “CCT is the business in our portfolio with the highest growth potential, largest margin expansion potential and the richest opportunity for continuous improvement.” — Luca Savi, Chief Executive Officer and President · 2026-11-05 That is a meaningful re-ranking. For several quarters the margin crown jewel was MT, and CCT the segment carrying kSARIA dilution. Now CCT prints a record 22% margin (kSARIA itself above 19%), broad-based across controls (+34% orders), connectors (+37% after +38% in Q2) and kSARIA — which management described as growing 146% in prepared remarks and 136% in the Q&A, a small slip worth noting for anyone modelling the lumpy defence piece. The visibility claim is strong: backlog for Q4 and 2027 up more than 30% year-over-year, the long-dated platform book up more than 100%. Meanwhile MT's message shifted from defence to a floor. In August the language was “consolidate and maintain this level of margin for the full year... It's solid rock.” — Luca Savi, Chief Executive Officer and President · 2026-08-06 Now: “21% now is the new floor... targeting our long-term target by 2030 of 23% independently from the growth in the market.” — Luca Savi, Chief Executive Officer and President · 2026-11-05 The bridge is technology — the Geo Pad formulation entering production for a European OEM in Q1 2028, electronic brakes first visible in China — plus the admission that OEM commercial pressure only intensifies: “it has always been tough, and it gets tougher and tougher.” — Luca Savi, Chief Executive Officer and President · 2026-11-05 The continuous improvement playbook is now explicitly a transferable asset, with Shenzhen's connector plant cited as already running MT-style on-time delivery near 99%.

The balance sheet pays for the ambition

Here the fundamentals tell a sharper story than the press release. Effective net cash flipped from +$1.22 billion at 2025Q4 to −$2.78 billion in 2026Q1 and −$2.4 billion last quarter — the arithmetic of a transformational deal funded with debt and equity. Liabilities to assets jumped to 56.4%, from 35% a year ago. Management is executing the paydown fast: over $200 million of debt retired in Q3, leverage down to 2.3x and guided to roughly 2.1x by year-end, plus $50 million of buybacks in the quarter and $150 million year-to-date. Which makes the change in M&A tone the most forward-looking signal on the call. Through the spring and summer the line was bolt-ons only, small by construction: “Obviously, they're going to be small in size, right? Nothing large.” — Luca Savi, Chief Executive Officer and President · 2026-05-06 Today:

So I would say the focus right now continue and generate the cash, deliver on the synergies, pay down the debt and be ready for something larger in 12, 15 months.
Luca Savi, Chief Executive Officer and President · 2026-11-05

Hunting grounds are named: connectors in aero and defence, Flow Technologies, and product or technology gaps inside SPX FLOW's mixers and Nutrition & Health. That is a company telling you the consolidation clock restarts in about a year — and that SPX FLOW, ITT's largest acquisition, is meant to be a platform rather than a destination.

From slide to shop floor

The Middle East thread shows a similar migration from narrative to execution. In May it was “more planning and discussion” — Luca Savi, Chief Executive Officer and President · 2026-05-06; in August it was orders "shifting right" with funnel growth the consolation. Now the cost of the conflict is quantified and the orders are landing: Habonim in Israel keeps growing orders and revenue but “we are suffering a little bit on the operating margin because of the cost... high teens versus in the 20s” — Luca Savi, Chief Executive Officer and President · 2026-11-05, while Goulds Pumps in Dammam grows more than 20% for the year and booked good Saudi Aramco-linked work in Q3. The localization programme has moved from intent to assembly — Bran+Luebbe build in China and the Middle East, European footprint being resized "right now" — and Venezuela, long flagged as a latent Bornemann tailwind, shows up as an actual oil-and-gas order win. Add European defence orders at KONI and kSARIA on submarine, F-35 and missile programmes, and ITT is riding the same defence-modernisation wave visible across the industrial tape, from missile defense backlogs at the primes to counter-UAS and drone awards elsewhere. What the tape is voting on is price. At 26x operating income and roughly 41.5x net income — on GAAP figures still weighed down by acquisition amortisation — ITT is no longer a cyclical-industrial multiple. The strategy is sound and it is being executed rigorously; the 21% margin, the $8.58 EPS and the 2.1x leverage target are all real. But the stock's six-month stall says the market has already paid for the cost synergies and is now waiting on the growth half of the SPX FLOW story — the part management itself says takes time. That is the quarter in one line: exceptional execution, an unproven cross-sell, and a clock now ticking toward a larger deal.